PortViewPortView
Emergent BioSolutions logo

Emergent BioSolutions (EBS) Stock Analysis

NYSEHealthcareDrug Manufacturers - Specialty & Generic

$6.45+3.62%
1-year price historyRange $4.45 – $13.90
52-week range$6.45
$4.36$14.06

What Emergent BioSolutions does

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.

Key metrics

Market cap
$332.54M
P/E (TTM)
4.48
EPS (TTM)
$1.44
Beta
2.36
Dividend yield
0.00%
Revenue / share
$14.93
50-day avg
$6.80
200-day avg
$9.09
52-week high
$14.06
52-week low
$4.36
CEO
Joseph C. Papa Jr.

ETFs linked to EBS

Broad-market and Healthcare sector ETFs an investor holding Emergent BioSolutions is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EBS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze EBS in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Emergent BioSolutions?
Emergent BioSolutions trades under the ticker EBS on NYSE.
Which exchange is EBS listed on?
EBS is listed on NYSE.
What sector does Emergent BioSolutions operate in?
Emergent BioSolutions is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
How can PortView help analyze EBS in a portfolio?
PortView shows EBS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.